Show simple item record

dc.contributor.authorUgurel, Sen_US
dc.contributor.authorRöhmel, Jen_US
dc.contributor.authorAscierto, PAen_US
dc.contributor.authorFlaherty, KTen_US
dc.contributor.authorGrob, JJen_US
dc.contributor.authorHauschild, Aen_US
dc.contributor.authorLarkin, Jen_US
dc.contributor.authorLong, GVen_US
dc.contributor.authorLorigan, Pen_US
dc.contributor.authorMcArthur, GAen_US
dc.contributor.authorRibas, Aen_US
dc.contributor.authorRobert, Cen_US
dc.contributor.authorSchadendorf, Den_US
dc.contributor.authorGarbe, Cen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-15T16:02:59Z
dc.date.issued2017-09en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28756137en_US
dc.identifierS0959-8049(17)31079-1en_US
dc.identifier.citationEur J Cancer, 2017, 83 pp. 247 - 257en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1141
dc.identifier.eissn1879-0852en_US
dc.identifier.doi10.1016/j.ejca.2017.06.028en_US
dc.description.abstractThe treatment of metastatic melanoma is still undergoing a process of major change. The two most important novel therapeutic strategies, selective kinase inhibitors and immune checkpoint blockers, both significantly prolong survival times of patients with advanced metastatic disease. Different agents, dose regimens and combinations have been tested against each other vigorously within these two groups. However, results from prospective head-to-head comparative studies of both strategies are still lacking. We performed an exploratory analysis of survival data from selected clinical trials representative for the new treatment strategies in advanced metastatic melanoma. Eighty-three Kaplan-Meier survival curves from 25 trials were digitised and grouped by therapeutic strategy and treatment line. For each of these groups, mean survival curves were generated for progression-free (PFS) and overall survival (OS) by weighted averaging. Survival curves grouped together by therapeutic strategy revealed a high concordance, particularly in the first-line setting. For kinase inhibitors, the most favourable PFS and OS in all therapy lines were observed for combined BRAF plus MEK inhibition. For immune checkpoint inhibitors, combined PD-1 plus CTLA-4 inhibition demonstrated the best survival outcome in all categories except for OS in first-line therapy. For the latter, combined PD-1 plus CTLA-4 inhibition showed similar outcomes as single-agent PD-1 inhibition. Comparison of kinase inhibitors and checkpoint blockers revealed a superiority of combined BRAF plus MEK inhibition within the first 6 months, later changing to a superiority of PD-1 blockers alone or in combination with CTLA-4 blockers. These results need confirmation by prospective clinical trials.en_US
dc.format.extent247 - 257en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectImmune checkpoint blockersen_US
dc.subjectKinase inhibitorsen_US
dc.subjectMelanomaen_US
dc.subjectSurvivalen_US
dc.subjectTherapyen_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectClinical Trials as Topicen_US
dc.subjectDrugs, Investigationalen_US
dc.subjectHumansen_US
dc.subjectImmunotherapyen_US
dc.subjectKaplan-Meier Estimateen_US
dc.subjectMelanomaen_US
dc.subjectMolecular Targeted Therapyen_US
dc.subjectProtein Kinase Inhibitorsen_US
dc.subjectSkin Neoplasmsen_US
dc.titleSurvival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.en_US
dc.typeJournal Article
dcterms.dateAccepted2017-06-21en_US
rioxxterms.versionofrecord10.1016/j.ejca.2017.06.028en_US
rioxxterms.licenseref.startdate2017-09en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfEur J Canceren_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume83en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record